370 likes | 509 Views
Predictive Modelling and its Benefits. Dr. Geraint Lewis Senior Fellow The Nuffield Trust. The Nuffield Trust. Charitable Organization founded in 1940 Formerly a grant-giving organization Since 2008 we have been conducting in-house research and policy analysis
E N D
Predictive Modelling and its Benefits Dr. Geraint Lewis Senior Fellow The Nuffield Trust
The Nuffield Trust • Charitable Organization founded in 1940 • Formerly a grant-giving organization • Since 2008 we have been conducting in-house research and policy analysis • Promote independent analysis and informed debate on healthcare policy across the UK
Outline • Rationale • Building a Predictive Model • Predictive Modelling in the UK • Other Applications of Risk Adjustment • Impactability Models
Why Predictive Modelling? • BMJ in paper* in 2002 showed KaiserPermanente in California seemed to provide higher quality healthcare than the NHS at a lower cost *Getting more for their dollar: a comparison of the NHS with California's Kaiser PermanenteBMJ 2002;324:135-143 • Kaiser identify high risk people in their population and manage them intensively to avoid admissions • Inaccurate Approaches: • Clinician referrals • Threshold approach (e.g. all patients aged >65 with 2+ admissions)
50 45 40 35 30 Average number of emergency bed days 25 20 15 10 5 0 - 1 + 1 + 2 + 3 + 4 - 5 - 4 - 3 - 2 Intense year Frequently-admitted patients
50 45 40 35 30 Average number of emergency bed days 25 20 15 10 5 0 Intense year - 5 - 4 - 3 - 2 - 1 + 1 + 2 + 3 + 4 Regression to the mean
50 45 40 35 30 25 Average number of emergency bed days 20 15 10 5 0 + 1 + 2 + 3 + 4 - 1 - 5 - 4 - 3 - 2 Intense year Emerging Risk
Kaiser Pyramid Small numbers of people at very high risk The Pyramid represents the distribution of risk across the population Large numbers of people at low risk [Size of shape is proportional to number of patients]
Patterns in routine data A&E data GP Practice data Inpatient data Outpatient data PARR Combined Model Census data
Name, Address, DOB 131178 131178 131178 J7KA42 131178 J7KA42 J7KA42 J7KA42 J7KA42 J7KA42 76.4 76.4 Name, Address, DOB Name, Address, DOB Name, Address, DOB 131178 Encrypted, linked data Inpatient Outpatient A&E GP Decrypted data with risk score attached
Randomised 5 Million Patient-Years of Data 5 Million Patient-Years of Data Development Validation Predictive Model 10 Million Patient-Years of Data
J7KA42 3LWZ67 YH8TPP G8HE9F 3LWZ67 2NX632 LG5DSD 3V9D54R J7KA42 G8HE9F YH8TPP 2NX632 3V9D54R J7KA42 YH8TPP G8HE9F 3LWZ67 2NX632 LG5DSD 3V9D54R LG5DSD Year 1 Year 2 Year 3 Inpatient Outpatient A&E GP Development Sample
J7KA42 3LWZ67 YH8TPP G8HE9F 3LWZ67 2NX632 LG5DSD 3V9D54R J7KA42 G8HE9F YH8TPP 2NX632 3V9D54R J7KA42 YH8TPP G8HE9F 3LWZ67 2NX632 LG5DSD 3V9D54R LG5DSD Year 1 Year 2 Year 3 Inpatient Outpatient A&E GP Development Sample
J7KA42 3LWZ67 YH8TPP G8HE9F 3LWZ67 2NX632 LG5DSD 3V9D54R J7KA42 G8HE9F YH8TPP 2NX632 3V9D54R J7KA42 YH8TPP G8HE9F 3LWZ67 2NX632 LG5DSD 3V9D54R LG5DSD Year 1 Year 2 Year 3 Inpatient Outpatient A&E GP Development Sample
True Positive 233UMB 833TY6 A89KP5 RF02UH I9QA44 6445JX 85H3D 833TY6 I9QA44 A89KP5 85H3D 233UMB A89KP5 6445JX 233UMB 6445JX RF02UH I9QA44 833TY6 RF02UH 85H3D False Negative False Positive True Negative Year 1 Year 2 Year 3 Validation Sample Inpatient Outpatient A&E GP
A89KP5 RF02UH 833TY6 I9QA44 85H3D 233UMB I9QA44 6445JX 833TY6 85H3D 6445JX 233UMB RF02UH A89KP5 Last Year This Year Next Year Inpatient Outpatient A&E GP Using the Model
£4,500 £4,000 £3,500 £3,000 Average cost per patient £2,500 £2,000 £1,500 £1,000 Actual £500 £0 0 10 20 30 40 50 60 70 80 90 Predicted Risk (centile rank) Distribution of Future Utilisation is Exponential
SPARRA Models being planned PARR & Combined Model PRISM
Scotland Wales PRISM model Welsh Predictive Risk Service • SPARRA • SPARRA-MD
Current work on a person-based resource allocation(PBRA) formula for England will potentially open up a much wider interest in these types of tools. • PBRA predicts per capita inpatient and outpatient costs of individuals over a future year and groups these costs at GP practice level
Comparative performance requires standardisation • This is to ensure that any observed differences in performance are not due to factors beyond the control of the organisation under scrutiny
Nuffield Trust is evaluatingcomplex preventive interventions including: • Telehealth and Telecare devices (WSD) • Partnerships for Older People Pilots (POPPs) • Virtual Wards (VWs) • Integrated care pilots (ICPs)
5 Evaluation of Integrated Care
Overcoming regression to the mean using a control group (1) Start of intervention
Overcoming regression to the mean using a control group (2) Start of intervention
Overcoming regression to the mean using a control group (3) Start of intervention
Overcoming regression to the mean using a control group (4) Start of intervention
Future Agenda • Ageing population and increasing prevalence of chronic diseases • Predictive Modelling is being facilitated by • Increasing availability of large data sets • Ability to link data at individual level pseudonymously • Improved computing power • Challenge for predictive modelling now will be in increasing the impact of preventive care on health outcomes and potential cost savings.
Potential Misuses • Dumping • Cream-skimming • Skimping How the output of predictive models are used • Case Management • Intensive Disease Management • Less Intensive Disease Management • Wellness Programs